ATP4A

Across TCGA pan-cancer cohorts, ATP4A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ATP4A data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATP4A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP4A expression acts as an unfavorable survival marker.

PDAC and CCRCC are the cancer types where ATP4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.554	0.992	.007	12	view →
CCRCC	OS	Median	III,IV	0.493	0.878	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ATP4A–PDAC (DFS)

Open the PDAC breakdown →